ILMNBy Calypso Research8 min read

Illumina (ILMN) Q4 2025 Earnings Analysis

Genome Gone Glum with 10% Drop on $1.2B Revenue

Key Takeaways

Illumina (ILMN) reported Q4 2025 earnings with revenue of $1.2B, representing a +5.0% year-over-year change. The stock moved -10.4% on earnings day.

The bull case: Clinical consumables strength, NovaSeq X momentum, and emerging multiomics/AI platforms drive a re-acceleration to high-single-digit growth and structurally higher margins by 2027, with upside from any recovery in research funding and China normalization.

The bear case: Persistent weakness in research and academic markets, competitive pricing pressure around $100 genomes, Somalogic and multiomics investments diluting margins longer than expected, and ongoing China/export uncertainties prevent Illumina from achieving its 2027 growth and margin targets.

Financial Highlights

  • Revenue: $1.2B (+5.0% YoY)
  • Gross Profit: $777M (67.0% margin, +1.1% YoY)
  • Operating Income: $256M (22.1% margin, +3.8% YoY)
  • Net Income: $334M
  • TTM Revenue: $4.3B

Stock Performance

  • Earnings Day Move: -10.4%
  • Year-to-Date: -10.3%
  • 1-Year Return: +28.3%
  • vs. S&P 500 (since earnings): +8.6%
  • vs. Nasdaq (since earnings): +11.7%

View live ILMN data, AI chat, and interactive debates on Calypso →

What Management Said

Here are the key debates and direct quotes from Illumina's Q4 2025 earnings call:

Sustainability of Margin Expansion and 2027 Targets (Including Somalogic Dilution)

Sentiment: Positive

"We have stepped ourselves into growth, and we believe we are in the right direction to deliver on the high single-digit growth in '27 in our core business... and now we are committing to another 130 basis points. So we are well on that trajectory... we will get as close to the 26% operating margin as possible in '27 also." — Jacob Thaysen
"So, Doug, your premise that next year, excluding Somalogic, that the exit rate operating margin for 2026 is higher than the average is that's usually our cyclicality in the business. So our full-year guide is 24.5%, and the exit rate in Q4 generally tends to be higher than that." — Ankur Dhingra

Durability of Clinical Consumables Growth vs. Ongoing Weakness in Research & Academic Funding

Sentiment: Positive

"We ended out the year with very strong performance on clinical with 20% clinical consumables growth in Q4 in '25 here. And we expect that momentum overall from the second half to continue... we have high mid-teens growth for our clinical business. But we also continue to see the channeling in the research academic environment." — Jacob Thaysen
"Within Q3, our growth was 2% ex-China. In Q4, it's ramped up to 7%. And so we took the average for the second half to bracket our overall guidance... clinical still grew in the double-digit rate. The research was dying down in the high single-digit rate... And then if research does improve, that certainly provides an upside." — Ankur Dhingra

NovaSeq X and Legacy Platform Dynamics (Pull-Through, Transition Timing, and Competitive Positioning)

Sentiment: Mixed

"For Xs, yes, about 200 to 240 for the year. Said on average, 50 to 60 a quarter is still quite good... we made a major software upgrade into X in 2025. The performance there has been running above the spec for a very large part of our customers. So X is performing at an extremely high level." — Ankur Dhingra
"If you think about the low end of the guide in the consumables is probably what we saw in Q3, and then we started to see momentum... On the instruments, I mean, we continue to see a lot of momentum... right now, we are guiding 50 to 60 placements, but many of our clinical customers continue to expand their placements." — Jacob Thaysen

Research & Academic Market Health, Core Labs, and NIH-Driven Recovery

Sentiment: Mixed

"Customers remain cautious with their purchasing decisions, though we are seeing signs of stabilization, including greater clarity around US policy and the funding environment... for now, we assume similar end market dynamics in '26 as we saw in 2025." — Jacob Thaysen
"We have, I think, the last eighteen months, really built out our relationship with the academic core labs... but we have done a very good job... to support both from when they have opportunities to acquire instruments... I do think now with Dr. Eric Green on board here, there's more opportunities to help them and navigate all through a challenging situation." — Jacob Thaysen

Competitive Pricing and the Shift from Cost per Genome to Total Workflow Economics

Sentiment: Mixed

"As I've mentioned, our customers are thinking way beyond just one parameter, one feature. They are more sophisticated than just looking at one element... we feel we have the portfolio. We have the pipeline. We have the capability to compete on all parameters." — Jacob Thaysen
"The conversations we are having with customers have shifted from cost per gigabase to the total cost of workflow, from sample preparation through analysis and interpretation, where integrated workflows and data quality matter most." — Jacob Thaysen

Bull Case

Clinical consumables strength, NovaSeq X momentum, and emerging multiomics/AI platforms drive a re-acceleration to high-single-digit growth and structurally higher margins by 2027, with upside from any recovery in research funding and China normalization.

Bear Case

Persistent weakness in research and academic markets, competitive pricing pressure around $100 genomes, Somalogic and multiomics investments diluting margins longer than expected, and ongoing China/export uncertainties prevent Illumina from achieving its 2027 growth and margin targets.

Looking Ahead

Investors will be closely watching Illumina's next quarterly report for continued execution, particularly around sustainability of Margin Expansion and 2027 Targets (Including Somalogic Dilution). With operating margins at 22.1%, margin trends will remain a focal point. The market's negative earnings-day reaction signals that investors need to see stronger execution, and the next earnings report will be a key catalyst for the stock.

Frequently Asked Questions

What was Illumina's revenue in Q4 2025?

Illumina reported Q4 2025 revenue of $1.2B, representing a +5.0% year-over-year change.

Did Illumina beat earnings expectations in Q4 2025?

The stock declined -10.4% on earnings day, suggesting the results fell short of market expectations. The current bull case centers on: Clinical consumables strength, NovaSeq X momentum, and emerging multiomics/AI platforms drive a re-acceleration to high-single-digit growth and structurally higher margins by 2027, with upside from any recovery in research funding and China normalization.

What is the bull case for ILMN stock?

The bull case for ILMN centers on: Clinical consumables strength, NovaSeq X momentum, and emerging multiomics/AI platforms drive a re-acceleration to high-single-digit growth and structurally higher margins by 2027, with upside from any recovery in research funding and China normalization.

What is the bear case for ILMN stock?

The bear case for ILMN centers on: Persistent weakness in research and academic markets, competitive pricing pressure around $100 genomes, Somalogic and multiomics investments diluting margins longer than expected, and ongoing China/export uncertainties prevent Illumina from achieving its 2027 growth and margin targets.

How has ILMN stock performed since its Q4 2025 earnings?

ILMN moved -10.4% on the day of its Q4 2025 earnings report, outperforming the S&P 500 by +8.6% since earnings. Year-to-date, the stock has returned -10.3%.

Browse all 400+ earnings reports →

Learn More

Analyze ILMN in Real Time

This is a static snapshot. For live financial data, AI-powered chat, and interactive earnings debates for Illumina and 400+ other stocks, explore the full platform.

Open ILMN on Calypso →

Calypso is an AI-powered equity research platform used by investment teams to cut earnings research time by over 80%.